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Abstract
Mitochondria must buffer the risk of proteotoxic stress to preserve bioenergetics, but the
role of these mechanisms in disease is poorly understood. Using a proteomics screen, we
now show that the mitochondrial unfoldase-peptidase complex ClpXP associates with the
oncoprotein survivin and the respiratory chain Complex II subunit succinate dehydrogenase
B (SDHB) in mitochondria of tumor cells. Knockdown of ClpXP subunits ClpP or ClpX
induces the accumulation of misfolded SDHB, impairing oxidative phosphorylation and ATP
production while activating “stress” signals of 50 adenosine monophosphate-activated pro-
tein kinase (AMPK) phosphorylation and autophagy. Deregulated mitochondrial respiration
induced by ClpXP targeting causes oxidative stress, which in turn reduces tumor cell prolif-
eration, suppresses cell motility, and abolishes metastatic dissemination in vivo. ClpP is uni-
versally overexpressed in primary and metastatic human cancer, correlating with shortened
patient survival. Therefore, tumors exploit ClpXP-directed proteostasis to maintain mito-
chondrial bioenergetics, buffer oxidative stress, and enable metastatic competence. This
pathway may provide a “drugable” therapeutic target in cancer.
Author Summary
As the powerhouse of the cell and a pivotal hub for oxidative stress, mitochondria must
tightly control the state of the proteins that they contain, quickly eliminating misfolded,
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aggregated, or otherwise damaged proteins. Here, we show that tumor mitochondria man-
age their set of proteins by assembling an integrated network of protein homeostasis, or
proteostasis, that controls both the folding and degradation of proteins. This protein com-
plex is formed by the unfoldase-peptidase ClpXP, survivin, and the Hsp90-like chaperone
TRAP-1, and regulates the function of the oxidative phosphorylation Complex II subunit
succinate dehydrogenase B (SDHB). We find that interference with this process impairs
energy production, promotes oxidative stress, and shuts down critical downstream signals
important for tumor cell proliferation, invasion, and metastatic dissemination in vivo. Our
results suggest that the mitochondrial proteostasis network may offer therapeutic opportu-
nities in advanced disease.
Introduction
The control of protein homeostasis, or proteostasis, occupies a central, evolutionary-conserved
role in organismal integrity and flexible adaptation to environmental “stress” [1]. This pathway
involves mechanisms of chaperone-directed protein (re)folding [2] as well as removal of aggre-
gated or misfolded proteins via proteolytic degradation [3]. Defects in either process impair
organelle function, in particular the endoplasmic reticulum (ER) [4] and mitochondria [5],
activating an unfolded protein response (UPR) that may culminate in cell death and tissue
damage [6].
There is also evidence that a heightened proteostatic threshold can contribute to disease, in
particular cancer, by buffering the risk of proteotoxic stress associated with the biosynthetic
needs of transformed cells. Accordingly, molecular chaperones of the heat shock protein-90
(Hsp90) family, including Hsp90 [7] and its homolog, TNFR-associated molecule-1 (TRAP-1)
[8], become overexpressed in mitochondria of tumor cells compared to normal tissues [9] and
preserve the folding and activity of key effectors of organelle homeostasis [10]. In turn, the
heightened proteostatic environment prevents the emergence of a mitochondrial UPR [11],
antagonizes cyclophilin D-dependent apoptosis [9], and maintains bioenergetics [10], includ-
ing oxidative phosphorylation [12], correlating with unfavorable disease outcome in cancer
patients [13].
What has remained unclear, however, is whether chaperone-directed protein folding is the
sole mechanism of mitochondrial proteostasis in cancer [10]. In this context, mitochondria
contain an evolutionary-conserved, ATP-dependent unfoldase-peptidase protein complex,
ClpXP [14], which mediates proteolytic removal of misfolded proteins [15]. There is evidence
that this pathway may regulate a mitochondrial UPR [16,17] and contribute to human disease
pathogenesis [18].
In this study, we investigated mechanisms of mitochondrial proteostasis as a potential
driver of tumor progression.
Results
Identification of ClpXP as a Novel Survivin-Associated Molecule
Previous studies have shown that a pool of the inhibitor-of-apoptosis (IAP) protein survivin
[19] localizes to mitochondria and contributes to the stability of oxidative phosphorylation
Complex II subunit succinate dehydrogenase B (SDHB) [20]. To further characterize this path-
way, we carried out a proteomics screen for additional survivin-associated molecules in mito-
chondria, using prostate adenocarcinoma PC3 cells as a tumor model (S1 Methods). In this
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screen, molecules associated with mitochondrial survivin comprised regulators of organelle
trafficking (Rab11), assembly of respiratory chain complexes (PTCD1), oxidative stress
(GPX4), mitoribosomal transferase activity (NSUN4), ubiquinone biosynthesis (COQ7), and
the AAA+ peptidase subunit of the ClpXP complex, ClpP (Fig 1A).
Consistent with these results, survivin immune complexes precipitated from mitochondria
of PC3 cells contained ClpP as well as TRAP-1 (Fig 1B) [20]. Reciprocally, ClpP co-immuno-
precipitated with survivin and TRAP-1 in tumor mitochondria (Fig 1C). In addition, ClpX and
ClpP mutually associated with each other as well as with SDHB in co-immunoprecipitation
experiments (Fig 1D), consistent with the assembly of a survivin-ClpXP [14]-SDHB complex
in tumor mitochondria. When analyzed for submitochondrial distribution, survivin, ClpP, and
TRAP-1 co-localized within the organelle matrix in PC3 cells (Fig 1E). In addition, a fraction
of TRAP-1 and survivin localized to the inner mitochondrial membrane (Fig 1E), in agreement
with recent observations [20].
To begin investigating the role of a survivin-ClpXP complex in mitochondria, we next
exposed PC3 cells to YM155, a small molecule survivin suppressant currently examined in
the clinic as an anticancer drug. In these experiments, YM155 treatment was associated with
reduced expression of ClpP (Fig 1F). As an independent approach, we next silenced survivin
using our validated small interfering RNA (siRNA) sequences [20]. Survivin knockdown
significantly reduced the levels of ClpP in mitochondria of PC3 cells, especially under
conditions of hypoxic stress (Fig 1G). In contrast, YM155 treatment (Fig 1F) or siRNA silenc-
ing of survivin (Fig 1G) did not affect the expression of mitochondrial chaperones Hsp70 or
Hsp60, or the voltage-dependent anion channel (VDAC). Next, we used cycloheximide block
experiments to quantify changes in ClpXP stability after survivin targeting. In these experi-
ments, YM155 treatment (S1A and S1B Fig) or siRNA silencing of survivin (S1C and S1D
Fig) resulted in accelerated turnover of ClpP, compared to control siRNA transfectants. This
regulation occurred at the protein level because survivin knockdown did not affect ClpP
mRNA expression (S1E Fig). In reciprocal experiments, transfection of PC3 cells with a survi-
vin variant engineered to selectively accumulate in mitochondria [20] increased ClpP levels
in mitochondria (Fig 1H). In contrast, targeting survivin with YM155 (Fig 1F) or siRNA
knockdown (S1C and S1D Fig) or, conversely, over-expression of mitochondrial survivin
(Fig 1H) did not appreciably affect ClpX levels. This suggests that ClpP is the primary bind-
ing partner of survivin in the ClpXP complex, consistent with the results of the proteomics
screen (Fig 1A).
ClpXP Regulation of Mitochondrial Complex II Folding and Activity
In mitochondria, survivin associates with the oxidative phosphorylation Complex II subunit,
SDHB, and regulates its stability [20]. Therefore, a role of ClpXP in this process [15] was next
investigated. First, siRNA silencing of ClpP resulted in increased accumulation of SDHB in
mitochondria, whereas COX-IV levels were not affected (S2A Fig). We next looked at the fold-
ing status of SDHB in these conditions. We found that siRNA silencing of ClpP caused the
accumulation of detergent-insoluble, i.e., misfolded, mitochondrial Complex II, whereas sub-
units of oxidative phosphorylation Complex I, III, IV, or V were not affected (Fig 2A). When
individual Complex II subunits were examined, ClpP knockdown selectively induced misfold-
ing and aggregation of SDHB at different detergent concentrations (Figs 2B, 2C and S2B). In
contrast, ClpP depletion did not affect the solubility of SDHA or other mitochondrial proteins,
including COX-IV (Fig 2A and 2B), VDAC, or citrate synthase (CS; S2B Fig), compared to
control transfectants. Aggregation and misfolding of SDHB, but not SDHA, after ClpP knock-
down was observed under different detergent conditions (NP-40; S2C and S2D Fig). In
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addition, siRNA silencing of ClpX similarly induced accumulation of aggregated or misfolded
SDHB (Figs 2D and S2E).
ClpXP Is Required for Mitochondrial Respiration
Next, we asked whether SDHB misfolding induced by ClpXP targeting affected mitochondrial
respiration. siRNA silencing of ClpX or ClpP did not affect mitochondrial Complex I activity
in PC3 cells, compared to control siRNA transfectants (Fig 3A). In contrast, knockdown of
ClpX or ClpP significantly reduced Complex II activity in PC3 cells (Fig 3B) as well as other
prostate cancer cell types, including C4-2 (S3A Fig) and DU145 (S3B Fig). This response was
specific because ClpX or ClpP targeting had no effect on mitochondrial Complex III (S3C Fig)
or Complex IV (S3D Fig) activity, whereas Complex V function was increased in ClpP- but not
ClpX-silenced PC3 cells (S3E Fig). Functionally, impaired Complex II activity after ClpXP tar-
geting reduced oxygen consumption (Fig 3C), increased the NAD/NADH ratio (Figs 3D and
S3F), and lowered overall ATP production (Fig 3E) in prostate cancer cells. Markers suggestive
of compensatory glycolysis, including glucose consumption (S3G Fig) or lactate production
(S3H Fig), were increased after ClpP- but not ClpX-silencing (S3G and S3H Fig). Consistent
Fig 1. Survivin-ClpXP interaction. (A) Heatmap of proteomics identification of mitochondrial proteins co-precipitated with an
antibody to survivin (SVV) or control IgG from PC3mitochondrial extracts. Two independent replicates per condition are shown. A
fold enrichment in spectra counts (SVV/IgG) is shown. (B–D) Mitochondrial extracts from PC3 cells were immunoprecipitated (IP)
with antibodies to survivin (SVV) (B), ClpP (C), ClpP or ClpX (D), or non-binding IgG and analyzed by western blotting. TCE, total
cell extracts. MTE, mitochondrial extracts. CS, citrate synthase. (E) Submitochondrial fractions representative of outer membrane
(OM), inter-membrane space (IMS), inner membrane (IM), or matrix were isolated from PC3 cells and analyzed by western blotting.
(F) PC3 cells were treated with vehicle (Veh) or small molecule survivin (SVV) suppressant YM155 and analyzed by western
blotting. (G) PC3 cells in normoxia (N) or hypoxia (H) were transfected with control non-targeting siRNA (Ctrl) or survivin (SVV)-
directed siRNA and analyzed by western blotting. (H) MCF-7 cells were transfected with vector or mitochondrial-targeted (mt)
survivin (SVV) cDNA and analyzed by western blotting. Expo, exposure.
doi:10.1371/journal.pbio.1002507.g001
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with defective bioenergetics, PC3 cells silenced for ClpP or ClpX exhibited increased phosphor-
ylation of the energy sensor 50 adenosine monophosphate-activated protein kinase (AMPK),
whereas total AMPK levels were not affected (Fig 3F). In turn, AMPK phosphorylation coupled
to downstream activation of autophagy, as determined by increased LC3-II conversion (Fig
3G), appearance of punctate LC3 staining by fluorescence microscopy (Fig 3H and 3I), accu-
mulation of autophagy markers p62 and Beclin-1, and increased phosphorylation of ULK1 on
its AMPK target site, Ser555 (Fig 3J).
Targeting Mitochondrial Proteases Induces Oxidative Stress
Based on these data, we next looked at the downstream consequences of defective mitochon-
drial respiration in ClpXP-targeted cells. siRNA silencing of ClpP or ClpX resulted in increased
total cellular superoxide production in prostate cancer cells (Fig 4A–4C). This response was
also associated with heightened production of mitochondria-specific reactive oxygen species
(ROS), compared to control transfectants (Fig 4D). To rule out potential off-target effects, we
next generated clones of PC3 and DU145 cells with stable shRNA knockdown of ClpP or ClpX
(S4A Fig). Stable depletion of ClpXP did not affect total mitochondrial content (S4B Fig) or
mitochondrial membrane potential (S4C Fig). In contrast, stable knockdown of ClpP increased
mitochondrial ROS production (Fig 4E and 4F), with hyperoxidation of mitochondrial peroxir-
edoxin III (Prx III), a marker of oxidative damage (Fig 4G). Total Prx III levels were not
Fig 2. ClpXP regulates mitochondrial SDHB folding. (A) PC3 cells were transfected with control siRNA (Ctrl) or ClpP-directed siRNA and
solubilized in the indicated concentrations of detergent (CHAPS), and insoluble fractions were analyzed by western blotting. The position of
oxidative phosphorylation complex (C) subunits are indicated. (B) PC3 cells were transfected with control siRNA (Ctrl) or ClpP-directed siRNA and
mixed with increasing concentrations of detergent (CHAPS), and insoluble fractions were analyzed by western blotting. Three independent
experiments per condition are shown. (C) Densitometric quantification of protein bands in control or ClpP siRNA transfectants, as in (B). Data are
the mean ± SEM of four (SDHB) or three (SDHA, COX-IV) independent experiments. (D) PC3 cells transfected with control siRNA (Ctrl) or ClpP-or
ClpX-directed siRNA were mixed with the indicated increasing concentrations of CHAPS, and insoluble material was analyzed by western blotting.
Raw data for this figure can be found in S1 Data.
doi:10.1371/journal.pbio.1002507.g002
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affected (Fig 4G). In contrast, stable shRNA silencing of ClpX did not significantly modulate
mitochondrial ROS production (Fig 4E and 4F) or Prx III hyperoxidation (Fig 4G), suggesting
that other mechanisms compensated for ClpX loss in the stable cell line. Treatment with the
antioxidant N-acetylcysteine (NAC) or mitochondrial ROS scavenger MitoTempo alone did
not rescue Prx III hyperoxidation after ClpXP knockdown (S4D Fig). Conversely, the combina-
tion of NAC plus MitoTempo reversed the hyperoxidation of Prx III in these cells (S4D Fig).
Functionally, we next asked if oxidative stress induced by ClpXP targeting was important for
Fig 3. ClpXP regulation of mitochondrial bioenergetics. (A andB) PC3 cells were transfected with control siRNA (Ctrl), ClpX- or ClpP-
directed siRNA, and mitochondrial extracts were analyzed for Complex I (A) or Complex II (B) activity. Right, Quantification of citrate
synthase-normalized mitochondrial complex activity. ***, p < 0.0001. (C–E) The indicated prostate cancer cell types were transfected with
control siRNA (Ctrl), ClpX- or ClpP-directed siRNA, and analyzed for changes in oxygen consumption rate (OCR,C), NAD/NADH ratio (PC3
cells,D), or ATP production (E). **, p < 0.006; ***, p < 0.0001. (F andG) PC3 cells transfected with the indicated siRNAs were analyzed by
western blotting. (H and I) siRNA-silenced PC3 cells and transfected with GFP-LC3 were analyzed by fluorescence microscopy (H) and the
number of LC3 puncta per cell were quantified (I). ***, p < 0.0001. (J) PC3 cells were transfected with control siRNA (Ctrl), CLpX- or ClpP-
directed siRNA, and analyzed by western blotting. Raw data for this figure can be found in S2 Data.
doi:10.1371/journal.pbio.1002507.g003
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autophagy induction in these settings. Consistent with this possibility, the combination of
NAC plus MitoTempo significantly attenuated LC3-II conversion in ClpP- or ClpX-silenced
cells (Fig 4H and 4I), and this response was amplified by the autophagic flux inhibitor hydroxy-
chloroquine (Fig 4H).
ClpXP Overexpression in Human Cancer
To complement the results obtained with tumor cell lines, we next looked at a potential differ-
ential expression of ClpXP in human cancer. First, ClpP was prominently upregulated in breast
Fig 4. Mitochondrial ROSmodulation by ClpXP. (A andB) PC3 cells transfected with control siRNA (Ctrl) or ClpX- or ClpP-directed siRNA
were labeled with CellROX Green Reagent by flow cytometry (A), and staining intensity was quantified (B). H2O2 was a control oxidative
stimulus. **, p = 0.004; ***, p < 0.0001. (C) The indicated prostate cancer cell types were analyzed for total ROS production as in (A).
*, p = 0.03–0.04; **, p = 0.001; ***, p = 0.0008–<0.0001. (D) PC3 cells transfected with the indicated siRNAs as in (A) were analyzed for
MitoSOX red mitochondrial superoxide reactivity by fluorescence microscopy and quantified. H2O2 was a control oxidative stimulus.
**, p = 0.001; ***, p = 0.0004–0.0001. (E and F) PC3 cells stably transduced with control pLKO or shRNA to ClpX or ClpP were analyzed for
mitochondrial superoxide production by fluorescence microscopy (E), and staining intensity was quantified (F). ***, p = 0.0004–0.0001. (G)
PC3 cells stably transduced with pLKO or ClpX- or ClpP-directed shRNA were analyzed by western blotting. (H) PC3 cells transfected with
control siRNA or ClpX- or ClpP-directed siRNA were incubated with vehicle (Veh) or the combination of antioxidants NAC (N) plus
mitochondrial-directed MitoTempo (MT) and analyzed by western blotting in the absence or presence of the autophagic flux inhibitor
hydroxychloroquine (HCQ). (I) Densitometric quantification of LC3-II/I ratio in vehicle (Veh) or antioxidant-treated PC3 cells in (H). Raw data for
this figure can be found in S3 Data.
doi:10.1371/journal.pbio.1002507.g004
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adenocarcinoma MCF-7 cells, compared to non-tumorigenic breast epithelial MCF-10A cells
(Fig 5A). Similarly, ClpP was highly expressed in primary tissue samples of human prostatic
adenocarcinoma, but not normal prostate epithelium (Fig 5B). For comparison, another prote-
ase involved in mitochondrial protein quality control, LonP1, was expressed in normal prostate
but not prostate cancer (Fig 5B). When applied to tissue extracts of patient-derived tumor sam-
ples, an antibody to ClpP reacted with a predominant single band by western blotting (S5A
Fig), reinforcing its specificity. Immunohistochemical staining of a universal cancer tissue
microarray demonstrated that ClpP was overexpressed in virtually every human malignancy
examined (Fig 5C), with intense cytoplasmic staining in the tumor cell population (Figs 5D
and S5B). ClpP expression in cancer patients was independent of grade (colon adenocarcinoma
and CNS tumors), Gleason score (prostate adenocarcinoma), histotype (lung cancer), or
aggressive versus indolent lymphomas (S5C Fig). Conversely, ClpP levels were increased in his-
totypes of breast adenocarcinoma compared to normal epithelium (S5C Fig). In addition, ClpP
became more prominently expressed in metastatic non-small cell lung cancer (NSCLC), com-
pared to non-metastatic lesions, with the highest levels in brain-metastatic NSCLC (Figs 5E, 5F
and S5D). In contrast, no difference in the percentage of ClpP-positive cells was observed in
primary or metastatic NSCLC (Fig 5G). Consistent with these results, bioinformatics meta-
analysis of public databases (PrognoScan) revealed that ClpP expression correlated with poorer
outcome in 9 out of 14 analyzed datasets (64%; S2 Table and Fig 5H–5J), whereas ClpP levels
were associated with better prognosis (S2 Table) in only one dataset (Melbourne). Importantly,
high levels of ClpP expression were associated with shortened distant metastasis-free survival
(S2 Table) in patients with breast adenocarcinoma (Fig 5H) and uveal melanoma (Fig 5I) and
in abbreviated relapse-free survival in lung adenocarcinoma (Fig 5J).
Regulation of Tumor Cell Proliferation by ClpXP
Based on these results, we next asked how ClpXP influenced tumor progression. In a first series
of experiments, knockdown of ClpP or ClpX partially reduced tumor cell proliferation (Figs
6A and S6A) and inhibited colony formation (Figs 6B, 6C and S6B), a marker of tumorigenic-
ity. The effect of ClpXP silencing on tumor cell proliferation was cell-type-specific and more
pronounced after knockdown of ClpP compared to ClpX (S6A Fig). In addition, silencing of
ClpP or ClpX minimally reduced proliferation of non-metastatic breast adenocarcinoma
MCF-7 cells, and non-tumorigenic breast epithelial MCF-10A cells were not affected (S6A
Fig). When characterized in sensitive PC3 cells, knockdown of ClpXP resulted in lower levels
of cyclins A, B1, and D1 (Fig 6D), reduced number of BrdU-positive cells (S6C Fig), and accu-
mulation of cells with G1 DNA content (S6D Fig), consistent with cell cycle arrest.
Next, we looked at the mechanism(s) of ClpXP regulation of tumor cell proliferation. First,
silencing of ClpP or ClpX in MCF-7 cells had little to no effect on mitochondrial Complex II
activity (S6E Fig) and oxygen consumption rate (OCR, S6F Fig), thus mirroring the marginal
sensitivity of these cells to ClpXP targeting (S6A Fig). In addition, ClpP or ClpXP knockdown
did not reduce Complex II activity (S6G Fig) or OCR (S6H Fig) in non-tumorigenic MCF-10A
cells, further linking impaired mitochondrial respiration induced by ClpXP targeting to
reduced tumor cell proliferation. Based on these results, we next asked if aberrant ROS produc-
tion associated with ClpXP targeting interfered with tumor cell proliferation. Consistent with
this possibility, the combination of antioxidants NAC plus MitoTempo (MT) restored tumor
cell proliferation (Fig 6E) and colony formation (Fig 6F) in ClpP-silenced PC3 cells. Similarly,
transfection of the ROS scavenger MnSOD rescued the defect of cell proliferation induced by
ClpP knockdown (Fig 6G). Finally, ClpXP depletion further sensitized tumor cells to “stress sti-
muli,” with more sustained inhibition of tumor cell proliferation mediated by oxidative stress
Mitochondrial Proteostasis in Metastasis
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Fig 5. ClpP expression in human cancer. (A andB) Breast adenocarcinoma MCF-7 cells, non-tumorigenic breast epithelial
MCF-10A cells (A), or primary human tissue samples representative of normal prostate or prostatic adenocarcinoma (B) were
analyzed by western blotting. (C) Immunohistochemistry (IHC) score of ClpP expression in the indicated primary human
tumors arrayed in a universal cancer tissue microarray. LN, lymph nodes; CNS, central nervous system. (D) IHC staining and
Aperio quantification of ClpP expression in the indicated human tumor types. AdCa, adenocarcinoma; HCC, hepatocellular
Mitochondrial Proteostasis in Metastasis
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carcinoma; Endom, endometrial AdCa. (E) Aperio quantification of ClpP IHC expression in primary tissue samples of non-
small cell lung cancer (NSCLC) that developed (met) or did not develop (no met) distant metastases or brain metastases
(brain met) during a 5-y follow-up. (F) Quantification of ClpP staining intensity in the NSCLC cases in (E). (G) Quantification of
ClpP-positive cells in primary and brain metastatic NSCLC. (H–J) Kaplan-Meier curves of metastasis-free survival (H and I) or
relapse-free survival (J) in the indicated patient series with high or low expression of ClpP. AdCa, adenocarcinoma. Raw data
for this figure can be found in S4 Data.
doi:10.1371/journal.pbio.1002507.g005
Fig 6. ClpXP regulation of tumor cell proliferation. (A) PC3 cells were transfected with control siRNA (Ctrl) or ClpX- or ClpP-directed siRNA and
analyzed for cell proliferation at the indicated time intervals by direct cell counting. (B andC) PC3 or DU145 cells stably transduced with pLKO or ClpX- or
ClpP-directed shRNA were analyzed for colony formation by crystal violet staining after 7 d (B, PC3) and quantified (C). *, p = 0.01; **, p = 0.006. (D) PC3
cells transfected with the indicated siRNAs as in (A) were analyzed by western blotting. (E and F) PC3 cells transfected with the indicated siRNAs (E) or
shRNAs (F) were incubated with the combination of antioxidants NAC (N) plus mitochondrial-directed MitoTempo (MT) and analyzed for cell proliferation
by direct cell counting (E) or colony formation (F). *, p = 0.028; **, p = 0.0026. (G) PC3 cells treated with control siRNA (Ctrl) or ClpP-directed siRNA were
transfected with vector or MnSOD cDNA, and analyzed for cell proliferation by direct cell counting. **, p = 0.001. (H) PC3 cells stably transduced with
pLKO or ClpX- or ClpP-directed shRNA were incubated with the indicated increasing concentrations of H2O2 (mM) and analyzed for inhibition of cell
proliferation by direct cell counting. (I and J) PC3 cells transfected with the indicated siRNAs were incubated with increasing galactose:glucose ratios (I) or
amino acid-deprived medium (50% amino acids, J) and analyzed for cell proliferation by direct cell counting. FU, fluorescence units. (K) PC3 cells
transfected with ClpP-directed siRNA were reconstituted with ClpP cDNA and analyzed by western blotting. Raw data for this figure can be found in S5
Data.
doi:10.1371/journal.pbio.1002507.g006
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(H2O2, Fig 6H), high galactose:glucose ratios (Fig 6I), or amino acid deprivation (50% amino
acids, Fig 6J). We next reconstituted ClpP-silenced PC3 cells with siRNA-insensitive ClpP
cDNA to test the specificity of these findings. Re-expression of ClpP under these conditions
rescued the phosphorylation of Akt, Src, and p70S6K in ClpP-silenced cells (Fig 6K). In addi-
tion, re-expression of ClpP reversed the induction of autophagy (S555 phosphorylation of
ULK1), AMPK signaling (ACC phosphorylation), and oxidative stress (Prx III hyperoxidation)
induced by ClpP silencing (Fig 6K).
ClpXP Regulation of Tumor Cell Invasion and Metastasis
A potential participation of ClpXP in other tumor traits was investigated next, and we focused
on cell motility, which requires mitochondrial bioenergetics [20]. siRNA knockdown of ClpP
or ClpX inhibited directional PC3 cell migration in a wound closure assay (Fig 7A and 7B), and
suppressed tumor cell invasion across Matrigel-coated Transwell inserts (Figs 7C and S7A).
This response was specific because reconstitution of ClpP-silenced cells with a ClpP cDNA
restored tumor cell motility in a wound closure assay (Fig 7D). Mechanistically, the combina-
tion of antioxidants NAC plus MitoTempo rescued the defect of tumor cell invasion mediated
by ClpP knockdown (Fig 7E), demonstrating that increased ROS production in these settings
was responsible for the inhibition of cell motility.
Next, we mapped the signaling requirements of ClpXP regulation of tumor cell motility. In
these experiments, siRNA silencing of ClpP attenuated Akt (S473) phosphorylation (S7B Fig)
and lowered the expression of cell motility effectors Caveolin-1 (Cav1) and Axl (S7B Fig).
ClpXP knockdown was marginally effective (S7B Fig), and no changes in Cav1 mRNA levels
were observed in control or ClpP siRNA transfectants (Fig 7F). Exposure of tumor cells to the
oxidative stressor H2O2 mimicked this response, causing hyperoxidation of Prx III and loss of
Cav1 expression (S7C Fig). Accordingly, siRNA silencing of Cav1 in PC3 cells was sufficient to
reduce the levels of phosphorylated Akt (S473) (S7D Fig) and suppressed tumor cell migration
and invasion, compared to control transfectants (S7E Fig). To validate a role of Cav1 in this
cell motility pathway, we next reconstituted ClpP- or ClpX-depleted cells with a Cav1 cDNA.
Re-expression of Cav1 in these settings restored Akt phosphorylation (Fig 7G) and rescued the
defect of tumor cell invasion (Fig 7H) after ClpP, but not ClpX knockdown. In contrast, recon-
stitution of ClpXP-targeted cells with an Akt cDNA had no effect (S7F Fig).
Finally, we asked if ClpXP regulation of tumor cell motility was important for metastasis in
vivo. Intra-splenic injection of PC3 cells transfected with control shRNA gave rise to extensive
metastatic dissemination to the liver of immunocompromised mice within 11 d of injection
(Fig 7I and 7J). In contrast, stable silencing of ClpX or ClpP in these cells suppressed the size,
number, and extent of liver metastases at the same time interval (Fig 7I and 7J).
Discussion
In this study, we have shown that the unfoldase-peptidase ClpXP forms a complex with survi-
vin and the Hsp90-like chaperone TRAP-1 in mitochondria of tumor cells. This interaction
maintains protein quality control and function of the oxidative phosphorylation Complex II
subunit SDHB. Accordingly, genetic targeting of ClpXP causes the accumulation of misfolded
SDHB, resulting in impaired bioenergetics, oxidative damage, and activation of stress signals,
including autophagy. ClpXP is dramatically upregulated in primary and disseminated human
tumors, correlates with shortened patient survival, and mechanistically supports tumor cell
proliferation, cell motility, and heightened metastatic competence in vivo.
Extensively studied in bacteria [21] and proposed as a regulator of cell persistence [22], the
ClpXP multimolecular complex [23] comprises a ClpX subunit that functions as an ATPase-
Mitochondrial Proteostasis in Metastasis
PLOS Biology | DOI:10.1371/journal.pbio.1002507 July 7, 2016 11 / 21
directed unfoldase for unstructured protein substrates and an internal caseinolytic peptidase,
ClpP, which degrades the translocated, unfolded peptides [14]. Although this proteasome-like
arrangement is conserved in mammalian cells [15], the data presented here suggest that the
ClpP and ClpX subunits may not have completely overlapping function(s) in tumor mitochon-
dria, especially with respect to Akt activation and Cav1-dependent tumor cell motility. It is
possible that these different responses reflect individual mitochondrial proteins independently
regulated by ClpP or ClpX, or, alternatively, the coupling of individual ClpXP subunits to sepa-
rate regulators of downstream signaling.
Fig 7. Requirement of ClpXP for tumor cell invasion andmetastasis. (A andB) PC3 cells transfected with control siRNA (Ctrl) or ClpX- or ClpP-directed
siRNA were analyzed for directional cell migration in a wound closure assay by light microscopy (ClpP, A), and wound surface area was quantified after 18
h (B). ***, p < 0.0001. (C) PC3 cells stably transduced with pLKO or ClpX- or ClpP-directed shRNA were analyzed for cell invasion across Matrigel-coated
inserts. ***, p < 0.0001. (D) PC3 cells transfected with ClpP-directed siRNA were reconstituted with ClpP cDNA and analyzed for cell migration in a wound
closure assay as in (A andB). (E) PC3 cells transfected with control siRNA (Ctrl) or ClpX- or ClpP-directed siRNA were analyzed for Matrigel invasion in the
presence of vehicle (Veh) or the combination of antioxidants NAC (N) plus MitoTempo (MT). ***, p < 0.0001. (F) PC3 cells transfected with control siRNA
(Ctrl) or ClpP-directed siRNA were analyzed for Caveolin-1 (Cav1) mRNA levels by quantitative PCR. (G andH) PC3 cells were transfected with the
indicated siRNAs, reconstituted with vector or Cav1 cDNA, and analyzed by western blotting (G) or Matrigel invasion (H). ***, p < 0.0001. (I) PC3 cells
stably transduced with pLKO or ClpX- or ClpP-directed shRNA were injected in the spleen of immunocompromised mice and livers collected after 11 d,
which were analyzed by hematoxylin-eosin staining and light microscopy. (J) Quantification of metastatic burden (%metastasis, top), number of metastatic
foci (middle), and size of metastatic foci (bottom) in mice intrasplenically injected with shRNA-transduced PC3 cells as in (I). **, p = 0.002; ***, p < 0.0001.
Raw data for this figure can be found in S6 Data.
doi:10.1371/journal.pbio.1002507.g007
Mitochondrial Proteostasis in Metastasis
PLOS Biology | DOI:10.1371/journal.pbio.1002507 July 7, 2016 12 / 21
The interaction between TRAP-1 [10] and ClpXP [14] described here brings together the
two main mechanisms of proteostasis: chaperone-regulated protein folding (TRAP-1) and pro-
teolytic removal of misfolded molecules (ClpXP) in a single, functional continuum. A mito-
chondrial pool of survivin contributes to this proteostasis network, potentially as a scaffolding
protein that binds both ClpP (this study) and TRAP-1 [20], and contributes to the stability of
the complex. Consistent with the earlier elucidation of a TRAP-1 proteome in tumor mito-
chondria [10], a key substrate of the proteostasis network identified here was the iron-sulfur
SDHB subunit of oxidative phosphorylation Complex II. The biochemical requirements of
mitochondrial respiration and electron transport chain are well understood [24], but the possi-
bility that these activities may depend on a carefully orchestrated balance of protein folding/
protein clearance, especially in the proteotoxic-prone environment of tumor mitochondria [5],
has not been widely considered. Consistent with this possibility, perturbation of the mitochon-
drial proteostasis network by TRAP-1 targeting [10] or ClpXP knockdown (this study) caused
SDHB degradation or, conversely, accumulation of misfolded or aggregated SDHB. The exqui-
site specificity of this response, in which none of the other oxidative phosphorylation com-
plexes are affected, highlights a potential unique propensity of SDHB to protein misfolding,
especially in tumor mitochondria, or, alternatively, a more stringent requirement of protein
quality control to enable efficient Complex II activity.
Irrespective, the loss of SDHB due to defective proteostasis profoundly affected mitochon-
drial bioenergetics, with decreased oxygen consumption, loss of ATP production, and a pheno-
type of cellular “stress,” characterized by activation of a mitochondrial and ER UPR [11],
AMPK phosphorylation [25], stimulation of autophagy [12], and loss of mechanistic target of
rapamycin (mTOR) signaling [20]. As shown here, an important mediator of these responses
was the increased production of mitochondrial ROS and the ensuing oxidative damage likely
associated with a defective electron transport chain [24]. This model is consistent with other
data in the literature that homozygous deletion of TRAP-1 caused increased ROS production,
DNA damage, and reduced cell proliferation [26], whereas TRAP-1 overexpression is protec-
tive against oxidative stress [27,28]. Here, antioxidants that include a mitochondrial ROS scav-
enger, MitoTempo, prevented the activation of autophagy and rescued the defects of cell
proliferation and tumor cell invasion associated with ClpXP targeting, establishing a causal
role of mitochondrial oxidative stress in these tumor traits.
Although a role of TRAP-1 in tumor progression is recognized [29], the possibility that
ClpXP-directed proteostasis [14] may be also exploited in cancer has been proposed only
recently [30]. In that study, the ClpXP subunit ClpP was found overexpressed in a subset of
human acute myeloid leukemias, and pharmacologic or genetic targeting of ClpP impaired
mitochondrial oxidative phosphorylation, resulting in leukemia cell killing [30]. The data pre-
sented here extend these observations and demonstrate that ClpXP-directed proteostasis is
exploited in most human cancers, correlating with shortened patient survival. Where the two
studies diverge, however, is in the mechanistic underpinning of the proposed pathway. Here,
ClpXP was recognized as a pivotal component of a proteostasis network that, together with
TRAP-1 [10] and survivin [20], ensures mitochondrial homeostasis in tumors. In our hands,
and at variance with recent findings [30], targeting ClpXP only partially reduced tumor cell
proliferation and in a cell-type-specific manner, with no measurable effect on tumor cell viabil-
ity. Instead, we found that ClpXP was required to support directional tumor cell migration,
invasion, and heightened metastatic dissemination in vivo. Mechanistically, this pathway
involved increased phosphorylation of key cell motility kinases Akt and Src, and reconstitution
experiments in ClpP-silenced cells identified the membrane microdomain adapter caveolin-1
[31] as a novel, oxidative, stress-regulated mediator of tumor cell motility.
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As most epithelial tumors rewire their metabolism toward glycolysis [32], a role of mito-
chondrial bioenergetics in cancer has been controversial, and SDHB itself has been at times
dubbed as a “tumor suppressor.” On the other hand, oxidative phosphorylation remains an
important energy source in most cancers [33], fueling critical disease traits such as tumor
repopulation after oncogene ablation [34] and drug resistance [35]. The data presented here
reinforce this model and establish a key requirement of mitochondrial integrity for tumor cell
motility and metastatic competence in vivo. This conclusion fits well with other evidence that
oxidative phosphorylation is required for membrane lamellipodia dynamics, turnover of focal
adhesion complexes, and phosphorylation of cell motility kinases [20,36], supporting tumor
cell invasion and metastatic dissemination, in vivo [25,37]. In the context of a proteostasis net-
work, ClpXP may contribute to this response by efficiently removing misfolded or aggregated
SDHB molecules to preserve Complex II bioenergetics as well as buffering organelle oxidative
stress.
In summary, we have shown that the unfoldase-peptidase complex ClpXP [14] is universally
exploited in human cancer and contributes to a mitochondrial proteostasis network that con-
trols metabolic reprogramming and downstream signals of tumor cell proliferation, motility,
and metastatic competence in vivo. There is now considerable interest in targeting unique fea-
tures of tumor metabolism, including mitochondrial functions [38], as a novel approach to
cancer therapy. In this context, proof-of-concept studies have demonstrated that small mole-
cule targeting of mitochondrial Hsp90s [25] or ClpXP [30] is feasible and produces potent anti-
cancer activity in preclinical models. Together, this suggests that therapeutic inhibition of the
mitochondrial proteostasis network described here may provide a viable strategy to disrupt key
requirements of tumor progression.
Materials and Methods
Patient Samples
All patient-related studies were reviewed and approved by an institutional review board at Fon-
dazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan, Italy. A cohort of 53 patients
with single brain metastases who underwent surgical resection for curative purposes between
2010 and 2015 was retrieved from the archives of Fondazione IRCCS Ca’ Granda Ospedale
Maggiore Policlinico (Milan, Italy) and arranged in a tissue microarray (TMA), as described
[39]. The predominant primary cancer histotype of metastatic cases was non-small cell lung
cancer (NSCLC, n = 44). Nineteen NSCLC patients for which complete 5-y follow-up records
were available were included in the study. During follow-up, 9 NSCLC patients developed met-
astatic disease to the brain, whereas 10 patients had no evidence of metastasis (S1 Table). A
Cancer Universal TMA (CaU-TMA) representative of 13 different cancer types (10 cases for
each tumor type) was described previously [40].
Mitochondrial Protein Folding
Mitochondrial protein folding assays were performed as previously described [10]. Briefly,
mitochondrial fractions were isolated from PC3 cells transfected with control non-targeting
siRNA or ClpP- or ClpX-directed siRNA after 72 h and suspended in equal volume of mito-
chondrial fractionation buffer containing increasing concentrations of NP-40 (0%, 0.05%,
0.1%, 0.2%, 0.5%, or 2%) or CHAPS (0%, 0.1%, 0.25%, 0.5%, 1%, or 2.5%). Samples were incu-
bated for 25 min on ice with vortexing every 5 min, and detergent-insoluble protein aggregates
were isolated by centrifugation at 20,000 g for 20 min, separated on SDS polyacrylamide gels,
and analyzed by western blotting.
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Analysis of Bioenergetics
The various prostate cancer cell types were transfected with control non-targeting siRNA or
ClpP- or ClpX-directed siRNA for 48 h or 72 h and analyzed for ATP generation (BioChain
cat No. Z5030041) or oxygen consumption (ENZO Lifesciences cat. No. ENZ-51045-1), as
described previously [10]. In other experiments, fresh culture medium containing dialyzed FBS
was harvested after 2 h and examined for lactate production (Abcam cat No. ab65331). The
quantification of NAD+ or NADH was measured by enzymatic NADH recycling assay accord-
ing to the manufacturer’s instruction (BioVision Cat No. K337-100). Briefly, PC3 cells (6 x
105) transfected with control non-targeting siRNA or ClpP- or ClpX-directed siRNA were har-
vested after 72 h, and cell pellets were disrupted by two cycles of freezing and thawing in
NADH/NAD+ extraction buffer. Soluble fractions were collected by centrifugation at 20,000 g
for 5 min and processed for removal of NADH-consuming enzymes using YM-10 (Millipore).
For assessment of NADH content, the cycling assay was performed after decomposition of
NAD+ by heating at 60°C for 25 min, whereas the decomposition step was omitted for determi-
nation of total NAD+/H content.
Mitochondrial Oxidative Phosphorylation Complex Activity
Various prostate cancer cell types were analyzed for changes in oxidative phosphorylation
complex activity using Abcam reagents (Cat. no. ab109721—Complex I, ab109908—Complex
II, ab109905—Complex II/III, ab109909—Complex IV) and Cayman reagent (701000—Com-
plex V) using isolated lysed mitochondria, as described [10]. Briefly, tumor cells were trans-
fected with control non-targeting siRNA or ClpP-or ClpX-directed siRNA and validated for
protein knockdown by western blotting, and 2 μg of mitochondrial extracts from each condi-
tion were assayed for citrate synthase (CS) activity (ScienCell). Aliquots of mitochondrial
lysates with comparable CS activity were applied for determination of the individual mitochon-
drial complex function. Relative complex activities were calculated by determining the change
in absorbance over time in the linear range of the individual measurements.
ROS Analysis
To detect total ROS, ClpP- or ClpX-silenced prostate cancer cell types were incubated with
2.5 μM of CellROX Green Reagent (Invitrogen) for 30 min at 37°C, according to the manufac-
turer’s instructions. After three washes in PBS, pH 7.4, cells were harvested and analyzed on a
FACS Calibur flow cytometer, with the CellROX Green Reagent signal in FL1. Intact cells were
gated in the FSC/SSC plot to exclude small debris. The resulting FL1 data were plotted on a his-
togram. Superoxide production by mitochondria was visualized by fluorescence microscopy, as
described previously [36]. Briefly, 1.5 x 104 cells were grown on high optical quality 8-well μ-
slides (Ibidi) and stained with MitoSOX Red mitochondrial superoxide indicator (5 μM, 10
min) in complete medium, followed by extensive washing in warm complete medium. Stained
cells were imaged with a 40X objective on a Nikon TE300 inverted time-lapse microscope
equipped with a video system containing an Evolution QEi camera and a time-lapse video cas-
sette recorder. The atmosphere was equilibrated to 37°C and 5% CO2 in an incubation cham-
ber. Phase and red fluorescence (TRITC filter cube, excitation wavelength: 532–554 nm,
emission wavelength: 570–613 nm) images were captured. To quantitate superoxide levels, files
were imported into Image J and masks were manually created around the periphery of the cell
based on the phase image and subsequently applied to the TRITC channel to measure intensity.
A minimum of 100 cells were analyzed in each independent experiment to obtain mean values.
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Cell Migration and Invasion
The various tumor cell types suspended in 0.1% BSA/RPMI and seeded (1 x 105 cells) in the
upper compartment of 8 μM pore diameter BD Transwell membranes (BD) were quantified
for cell migration, as described [20]. For cell invasion, the Transwell membranes were coated
with Matrigel. In all experiments, NIH3T3 conditioned medium was placed in the lower com-
partment as a chemoattractant [25]. After 18 h incubation at 37°C, the Transwell membranes
from each insert were recovered and cells on the upper side (non-migratory) were scraped off
the surface. Cells on the lower side of the membrane were fixed in methanol, rinsed in water,
and mounted on glass slides with Vectashield medium containing DAPI (Vector Laboratories).
Migrated cells on each membrane were counted in five different fields at 20x magnification by
fluorescence microscopy.
Liver Metastasis Model
All experiments involving animals were carried out in accordance with the Guide for the Care
and Use of Laboratory Animals of the National Institutes of Health. Protocols were approved
by the Institutional Animal Care and Use Committee (IACUC) at The Wistar Institute. A liver
metastasis models was performed essentially as described previously [25]. Briefly, PC3 cells sta-
bly transfected with control pLKO or ClpP- or ClpX-directed shRNA at 80% confluency were
suspended in PBS, pH 7.4, and 50 μl containing 1 × 106 cells were injected in the spleen of 6–8
wk-old male NOD SCID gamma (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (Jackson
Laboratory). Spleens were removed the first day after injection to minimize potentially con-
founding effects on metastasis due to variable growth of primary tumors. Animals were sacri-
ficed 11 d after injection of the tumor cells, and their livers were resected, fixed in formalin,
and paraffin-embedded. Serial liver sections 500 μm apart (n = 15 per each condition) were
stained with hematoxylin and eosin and analyzed histologically. Metastatic foci were quantified
by morphometry and expressed as number and surface areas of metastatic tumor growth com-
pared to total surface area, as described [25].
Statistical Analysis
Data were analyzed using the two-sided unpaired t or chi-square tests using a GraphPad soft-
ware package (Prism 6.0) for Windows. Data are expressed as mean ± SD or mean ± SEM of
replicates from a representative experiment out of at least two or three independent determina-
tions. A p value of<0.05 was considered statistically significant.
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S1 Fig. Mitochondrial survivin regulation of ClpP. (A and B) PC3 cells were treated with
vehicle (Veh) or small molecule survivin (SVV) suppressant YM155, incubated with cyclohexi-
mide (CHX), and ClpP or SVV protein bands detected by western blotting after CHX release
(A) was quantified by densitometry (B). (C andD) The experimental conditions are as in (A
and B) except that PC3 cells were transfected with control siRNA (Ctrl) or SVV-directed
siRNA and protein bands detected by western blotting after CHX release (C) was quantified by
densitometry (D). (E) PC3 cells were transfected with control non-targeting siRNA (Ctrl) or
SVV-directed siRNA and analyzed for ClpP mRNA levels by quantitative PCR. Raw data for
this figure can be found in S7 Data.
(TIF)
S2 Fig. Analysis of protein folding. (A) PC3 cells were transfected with control siRNA (Ctrl)
or ClpP-directed siRNA and analyzed by western blotting. (B) PC3 cells transfected with con-
trol siRNA (Ctrl) or ClpP-directed siRNAs, as in (A), were solubilized in the indicated increas-
ing concentrations of detergent (CHAPS), and insoluble (top) or soluble (bottom) fractions
were analyzed by western blotting. CS, citrate synthase. (C andD) PC3 cells transfected with
control siRNA (Ctrl) or ClpP-directed siRNA were solubilized in the indicated increasing con-
centrations of detergent (NP-40) and detergent-insoluble bands were visualized by western
blotting (C) with quantification by densitometry (D). (E) PC3 cells were transfected with con-
trol non-targeting siRNA (Ctrl) or ClpP- or ClpX-directed siRNA and detergent-insoluble
SDHB bands visualized by western blotting were quantified by densitometry at the indicated
detergent (CHAPS) concentrations. Raw data for this figure can be found in S8 Data.
(TIF)
S3 Fig. ClpXP regulation of mitochondrial respiration. (A and B) Prostate cancer C4-2 (A)
or DU145 (B) cells were transfected with control non-targeting siRNA (Ctrl) or ClpP- or
ClpX-directed siRNA and analyzed for Complex II activity. Right, quantification of citrate
synthase-normalized Complex II activity. , p = 0.01; , p = 0.008. (C–E) PC3 cells transfected
with control siRNA (Ctrl) or ClpP- or ClpX-directed siRNA were analyzed for mitochondrial
Complex III (C), Complex IV (D), or Complex V (E) activity. Right, Quantification of citrate
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synthase-normalized mitochondrial complex activities. , p = 0.04. (F) siRNA-transfected PC3
cells, as in (C–E), were analyzed for NAD/NADH ratio. (G andH) PC3 cells transfected with
the indicated siRNAs were analyzed for glucose consumption (G) or lactate production (H).
, p< 0.0001. Raw data for this figure can be found in S9 Data.
(TIF)
S4 Fig. Characterization of stable cell lines. (A) PC3 cells were infected with control pLKO or
shRNA directed to ClpX or ClpP and selected in puromycin-containing medium, and the indi-
cated clones were analyzed by western blotting. (B and C) Control pLKO-transfectants or
ClpX (clone #59) or ClpP (clone #59) shRNA transfectants were analyzed for total mitochon-
drial content (B) or changes in mitochondrial membrane potential (C) by TMRM labeling and
flow cytometry. (D) PC3 cells were transfected with control siRNA (Ctrl) or ClpX- or ClpP-
directed siRNA, mixed with the ROS scavengers NAC (N) or MitoTempo (MT), alone or
in combination, and analyzed by western blotting. Raw data for this figure can be found in
S10 Data.
(TIF)
S5 Fig. ClpP expression in human tumors. (A) Tissue extracts from brain metastasis of non-
small cell lung cancer (NSCLC) were separated by SDS gel electrophoresis and analyzed with
an antibody to ClpP by western blotting. Undiff, undifferentiated; SCC, squamous cell carci-
noma; AdCa, adenocarcinoma. (B) Primary tissue samples representative of the indicated
tumor diagnoses were stained with an antibody to ClpP and analyzed by immunohistochemis-
try (IHC). Quantification of cytosolic ClpP staining in the marked tissue areas was carried out
using the Aperio software (Quantification). Ca, carcinoma, AdCa, adenocarcinoma; HL, Hodg-
kin’s Lymphoma; HG, high-grade; IDC, infiltrating ductal carcinoma; ILC, infiltrating lobular
carcinoma; GBM, glioblastoma. (C) Correlation between ClpP immunohistochemical (IHC)
staining in primary human tumors and tumor grade (Colon AdCa, CNS tumors), Gleason
score (prostate AdCa), lymphoma subtype (DLBCL, diffuse large B cell lymphoma; Follicular,
follicular lymphoma; Mantle, mantle cell lymphoma; HL, Hodgkin’s lymphoma); histotype
(lung cancer or breast AdCa; CIS, carcinoma in situ; IDC, infiltrating ductal carcinoma; ILB,
infiltrating lobular carcinoma). Mening, meningioma. Data are expressed as mean ± SEM of a
ClpP IHC score per each tumor type examined. (D) Primary tissue samples representative of
normal lung, non-small cell lung cancer (NSCLC) that developed (met) or not (no met) distant
metastases during a 5-years follow-up, or metastatic NSCLC to the brain were analyzed for
ClpP expression by immunohistochemistry (IHC), with quantification of marked areas by
Aperio. Raw data for this figure can be found in S11 Data.
(TIF)
S6 Fig. ClpXP regulation of tumor cell proliferation. (A) The indicated tumor cell types
were transfected with control siRNA (Ctrl) or ClpX- or ClpP-directed siRNA and analyzed
for changes in cell proliferation by direct cell counting. , p = 0.013–0.015; , p = 0.001–0.007;
, p< 0.0001. (B) PC3 cells stably transfected with control pLKO or shRNA to ClpX or ClpP
were analyzed for colony formation after 7 d by crystal violet staining. , p = 0.001–0.004. (C)
PC3 cells transfected with the indicated siRNAs were analyzed for BrdU incorporation by flow
cytometry, and the percentage of BrdU+ cells was quantified. , p = 0.004; , p< 0.0001. (D)
PC3 cells transfected as in (A) were analyzed for DNA content by propidium iodide staining
and flow cytometry, and the percentage of cells in each cell cycle phase was quantified. (E)
Breast adenocarcinoma MCF-7 cells were transfected with control siRNA (Ctrl) or ClpP- or
ClpX-directed siRNA and analyzed for Complex II activity. Right, Quantification of citrate
synthase-normalized Complex II activity. , p = 0.002. (F) MCF-7 cells transfected with the
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indicated siRNAs were analyzed for oxygen consumption rates (OCR). (G) Breast epithelial
MCF-10A cells were transfected with control siRNA (Ctrl) or ClpP- or ClpX-directed siRNA
and analyzed for Complex II activity. Right, Quantification of citrate synthase-normalized
Complex II activity. (H) siRNA-transfected MCF-10A cells as in (G) were analyzed for oxygen
consumption rates (OCR). Raw data for this figure can be found in S12 Data.
(TIF)
S7 Fig. ClpXP requirement for tumor cell invasion. (A) DU145 or LN229 cells were trans-
fected with control siRNAs or ClpX- or ClpP-directed siRNA and analyzed for Matrigel inva-
sion. , p< 0.0001. (B) LN229 cells were transfected with the indicated siRNAs as in (A) and
analyzed by western blotting. (C) PC3 cells were treated with the indicated increasing concen-
trations of H2O2 and analyzed by western blotting. (D and E) PC3 cells were transfected with
control siRNA (Ctrl) or Caveolin-1 (Cav1)-directed siRNA and analyzed by western blotting
(D) or changes in cell migration (Migr) or cell invasion (Inv) across Transwell membranes (E).
, p< 0.0001. (F) PC3 cells transfected with control siRNA (Ctrl) or ClpX- or ClpP-directed
siRNA were reconstituted with vector or Akt cDNA and analyzed for cell invasion in a Trans-
well assay. Raw data for this figure can be found in S13 Data.
(TIF)
S1 Methods. Supporting materials and methods.
(DOCX)
S1 Table. Patients’ characteristics. NSCLC, non-small cell lung cancer; PNET, pulmonary
neuroendocrine tumor; other cancers: breast adenocarcinoma (1), melanoma (1), colorectal
adenocarcinoma (1), ovarian carcinoma (1).
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